Allurion Technologies Inc (ALUR)

$1.17 -0.08 (-6.40%)
Market Cap 14.37M
Revenue (ttm) 32.11M
Net Income (ttm) -26.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -81.44%
Debt to Equity Ratio 0.00
Volume 1,060,300
Avg Vol 3,142,904
Day's Range N/A - N/A
Shares Out 12.28M
Stochastic %K 13%
Beta -0.43
Analysts Strong Sell
Price Target $5.50

Company Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Tur...

Industry: Medical Devices
Sector: Healthcare
Phone: 508 647 4000
Address:
11 Huron Drive, Natick, United States
MedicineMan777
MedicineMan777 Mar. 2 at 1:34 AM
$ALUR 🚀❤️
0 · Reply
19steve72
19steve72 Mar. 2 at 1:12 AM
$ALUR Uhoh big dip
0 · Reply
MedicineMan777
MedicineMan777 Mar. 2 at 1:09 AM
$ALUR 🚀
0 · Reply
MedicineMan777
MedicineMan777 Mar. 2 at 1:08 AM
$ALUR
0 · Reply
steve3079
steve3079 Mar. 1 at 11:53 PM
$ALUR Quiet board
0 · Reply
MedicineMan777
MedicineMan777 Mar. 1 at 8:04 PM
$ALUR
0 · Reply
MedicineMan777
MedicineMan777 Mar. 1 at 8:01 PM
$ALUR
0 · Reply
19steve72
19steve72 Mar. 1 at 6:24 PM
$ALUR bought 10000 friday Where is this going?
0 · Reply
JAXTWIN
JAXTWIN Mar. 1 at 5:56 PM
$ALUR if this runs to $3 this month, I will be mad lol.
0 · Reply
JAXTWIN
JAXTWIN Mar. 1 at 5:53 PM
$CATX did a little bit of a run so I’m glad I got into $ALUR when I did. Despite competition, I like the approach.
0 · Reply
Latest News on ALUR
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Feb 24, 2026, 9:15 AM EST - 5 days ago

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Allurion Receives U.S. FDA Approval

Feb 23, 2026, 9:00 AM EST - 6 days ago

Allurion Receives U.S. FDA Approval

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Feb 3, 2026, 9:00 AM EST - 26 days ago

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Jan 12, 2026, 8:30 AM EST - 6 weeks ago

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Nov 25, 2025, 9:25 AM EST - 3 months ago

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Nov 20, 2025, 9:00 AM EST - 3 months ago

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Nov 18, 2025, 9:00 AM EST - 3 months ago

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 10:21 AM EST - 3 months ago

Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 8:00 AM EST - 3 months ago

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Nov 11, 2025, 8:45 AM EST - 3 months ago

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

Nov 6, 2025, 4:05 PM EST - 4 months ago

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Sep 30, 2025, 4:05 PM EDT - 5 months ago

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 12:14 PM EDT - 7 months ago

Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Aug 5, 2025, 8:00 AM EDT - 7 months ago

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

Jul 22, 2025, 8:00 AM EDT - 7 months ago

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Jul 9, 2025, 4:05 PM EDT - 8 months ago

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

Jun 17, 2025, 8:00 AM EDT - 9 months ago

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

Allurion to Present at Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 9 months ago

Allurion to Present at Jefferies Global Healthcare Conference

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

May 27, 2025, 4:05 PM EDT - 9 months ago

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript

May 14, 2025, 2:44 PM EDT - 10 months ago

Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 8:00 AM EDT - 10 months ago

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

May 13, 2025, 4:05 PM EDT - 10 months ago

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

May 5, 2025, 4:05 PM EDT - 10 months ago

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

Allurion Announces Postponement of Special Meeting of Stockholders

Apr 3, 2025, 4:30 PM EDT - 11 months ago

Allurion Announces Postponement of Special Meeting of Stockholders

Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 10:44 AM EDT - 1 year ago

Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Mar 4, 2025, 4:05 PM EST - 1 year ago

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 1 year ago

Allurion to Participate in Upcoming Investor Conferences

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 20, 2025, 4:05 PM EST - 1 year ago

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Feb 19, 2025, 9:03 AM EST - 1 year ago

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Feb 18, 2025, 8:30 AM EST - 1 year ago

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

Allurion Relaunches in France

Feb 13, 2025, 8:30 AM EST - 1 year ago

Allurion Relaunches in France

Allurion Technologies Shares Are Up Today: What's Going On?

Jan 24, 2025, 1:25 PM EST - 1 year ago

Allurion Technologies Shares Are Up Today: What's Going On?

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Jan 24, 2025, 11:50 AM EST - 1 year ago

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Jan 24, 2025, 9:30 AM EST - 1 year ago

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Jan 23, 2025, 3:48 PM EST - 1 year ago

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Jan 21, 2025, 8:30 AM EST - 1 year ago

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Jan 14, 2025, 9:18 AM EST - 1 year ago

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Announces Positive Topline Results From AUDACITY Trial

Jan 8, 2025, 8:00 AM EST - 1 year ago

Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion Technologies, Inc. Announces Reverse Stock Split

Dec 24, 2024, 7:00 AM EST - 1 year ago

Allurion Technologies, Inc. Announces Reverse Stock Split

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Dec 2, 2024, 8:00 AM EST - 1 year ago

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Nov 25, 2024, 8:00 AM EST - 1 year ago

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:43 PM EST - 1 year ago

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

MedicineMan777
MedicineMan777 Mar. 2 at 1:34 AM
$ALUR 🚀❤️
0 · Reply
19steve72
19steve72 Mar. 2 at 1:12 AM
$ALUR Uhoh big dip
0 · Reply
MedicineMan777
MedicineMan777 Mar. 2 at 1:09 AM
$ALUR 🚀
0 · Reply
MedicineMan777
MedicineMan777 Mar. 2 at 1:08 AM
$ALUR
0 · Reply
steve3079
steve3079 Mar. 1 at 11:53 PM
$ALUR Quiet board
0 · Reply
MedicineMan777
MedicineMan777 Mar. 1 at 8:04 PM
$ALUR
0 · Reply
MedicineMan777
MedicineMan777 Mar. 1 at 8:01 PM
$ALUR
0 · Reply
19steve72
19steve72 Mar. 1 at 6:24 PM
$ALUR bought 10000 friday Where is this going?
0 · Reply
JAXTWIN
JAXTWIN Mar. 1 at 5:56 PM
$ALUR if this runs to $3 this month, I will be mad lol.
0 · Reply
JAXTWIN
JAXTWIN Mar. 1 at 5:53 PM
$CATX did a little bit of a run so I’m glad I got into $ALUR when I did. Despite competition, I like the approach.
0 · Reply
JAXTWIN
JAXTWIN Mar. 1 at 5:51 PM
$ALUR Watching this week. Promising stock so trying to learn a bit more.
0 · Reply
MedicineMan777
MedicineMan777 Feb. 28 at 3:11 PM
$ALUR
0 · Reply
MedicineMan777
MedicineMan777 Feb. 27 at 4:39 PM
$ALUR This will recover today it has to! look at all the interest charged on borrowed shares 273%.
0 · Reply
MedicineMan777
MedicineMan777 Feb. 27 at 2:39 PM
$ALUR
0 · Reply
MedicineMan777
MedicineMan777 Feb. 27 at 2:37 PM
$ALUR don’t panic some dumbass shorted 55,000 shares this morning but there is no more left
0 · Reply
MedicineMan777
MedicineMan777 Feb. 27 at 7:46 AM
$ALUR GLP-1 side effects injections and pills Nausea (most common) • Vomiting • Diarrhea • Constipation • Stomach pain • Bloating / fullness • Loss of appetite • Heartburn / reflux • Fatigue (sometimes) These happen because GLP-1 drugs slow stomach emptying. Less Common but More Serious • Gallbladder problems (gallstones, inflammation) • Pancreatitis (rare but serious — severe upper abdominal pain that may radiate to the back) • Dehydration (from prolonged vomiting/diarrhea) • Kidney problems (usually secondary to dehydration) • Worsening diabetic retinopathy (mainly noted with semaglutide in people with pre-existing eye disease) • Increased heart rate (mild in some people) Rare but Important Warning • Possible thyroid C-cell tumors (seen in rodents, unclear risk in humans) • These drugs are not recommended if someone has: • Personal or family history of medullary thyroid cancer • MEN2 (Multiple Endocrine Neoplasia type 2) Why Some People Stop The About 30–50%
0 · Reply
MedicineMan777
MedicineMan777 Feb. 26 at 7:02 PM
$ALUR The Allurion Program is offered in 80+ countries, and its products are registered in over 50 countries across Europe, the Middle East, Africa, Latin America, Asia-Pacific and North America • 📈 Patient Adoption: More than 150,000 patients have been treated with the Allurion Program globally, indicating usage by many clinics that offer it.
0 · Reply
spider521
spider521 Feb. 26 at 6:05 PM
$ALUR $WHLR $NMRA Green on red days...very strong
0 · Reply
Scandal2024
Scandal2024 Feb. 26 at 5:30 PM
$ALUR is this the stock that recently traded 117.2 trillion shares in one day?
1 · Reply
thattradeguy_
thattradeguy_ Feb. 26 at 12:46 PM
$ALUR
0 · Reply
MedicineMan777
MedicineMan777 Feb. 26 at 11:52 AM
$ALUR A JAMA Network Open study of >195,000 people found 36.5% had discontinued semaglutide GLP1 by 12 months overall. • Another large registry analysis from medscape.com/ found over half (≈52%) of adults taking semaglutide for weight loss were no longer on the drug by one year. They will turn to $ALUR for alternatives.
0 · Reply